{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:31:54Z","timestamp":1793287914767,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.015","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:07:17Z","timestamp":1791907637000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Estimation of Melphalan Exposure Predicts Disease Control and Toxicity After Autologous Hematopoietic Cell Transplantation for Multiple Myeloma"],"prefix":"10.1016","author":[{"given":"Natalia Tijaro","family":"Ovalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Cruz","family":"Sitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenden","family":"Bready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Zara","family":"Herskovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha S.","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryln Rose","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Jurgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.10.015_bib0001","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.10.015_bib0002","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.015_bib0003","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.10.015_bib0004","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.10.015_bib0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cncr.35056","article-title":"Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma","volume":"130","author":"Yan","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.10.015_bib0006","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m2 or 200 mg\/m2 for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) Study. A Report by the EBMT Chronic Malignancies Working Party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.10.015_bib0007","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-017-0581-x","article-title":"Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of Melphalan in patients undergoing hematopoietic stem cell transplantation","volume":"57","author":"Mizuno","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2026.10.015_bib0008","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of Melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2026.10.015_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High Melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose Melphalan and autologous transplantation","volume":"82","author":"Nath","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2026.10.015_bib0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40262-021-01093-z","article-title":"Population pharmacokinetics of Melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: towards individualized dosing regimens","volume":"61","author":"Shah","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2026.10.015_bib0011","doi-asserted-by":"crossref","first-page":"485.e1","DOI":"10.1016\/j.jtct.2022.05.003","article-title":"Evaluation of Melphalan exposure in lymphoma patients undergoing BEAM and autologous hematopoietic cell transplantation","volume":"28","author":"Dahi","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.015_bib0012","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-0716-3541-4_14","article-title":"Determination of busulfan and Melphalan in plasma by turbulent flow chromatography-tandem mass spectrometry","volume":"2737","author":"Schofield","year":"2024","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtct.2026.10.015_bib0013","article-title":"Non-compartmental Analysis","volume":"929","author":"J","year":"2012","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"10.1016\/j.jtct.2026.10.015_bib0014","article-title":"A method to determine pharmacokinetic parameters based on andante constant-rate intravenous infusion","volume":"7","author":"Yu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2026.10.015_bib0015","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.10.015_bib0016","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A phase IIb, multicenter, open-label, safety, and efficacy study of high-dose, propylene glycol-free Melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.015_bib0017","unstructured":"Bashir, Q. & Knape, C. Phase I\/II trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200."},{"key":"10.1016\/j.jtct.2026.10.015_bib0018","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2014.186","article-title":"Not too little, not too much\u2014just right! (Better ways to give high dose Melphalan)","volume":"49","author":"Shaw","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.015_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101162","article-title":"Optimizing high dose Melphalan","volume":"64","author":"Shah","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2026.10.015_bib0020","doi-asserted-by":"crossref","first-page":"384.e1","DOI":"10.1016\/j.jtct.2025.03.020","article-title":"High Melphalan exposure increases the risk of graft-versus-host disease in pediatric patients undergoing alpha-beta T-cell depleted haploidentical transplantation","volume":"31","author":"Dvorak","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.015_bib0021","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1016\/j.clml.2021.06.004","article-title":"Budesonide prophylaxis reduces the risk of engraftment syndrome after autologous hematopoietic cell transplantation in multiple myeloma","volume":"21","author":"Dhakal","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2026.10.015_bib0022","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.bbmt.2019.12.707","article-title":"Successful personalization of propylene glycol free Melphalan (PGF-MEL) for multiple myeloma (MM) and AL amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AHCT) using pharmacokinetic (PK)-directed dosing","volume":"26","author":"Shah","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.015_bib0023","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","article-title":"Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive b-cell non-Hodgkin lymphoma","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.10.015_bib0024","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1182\/bloodadvances.2023009708","article-title":"Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:39:35Z","timestamp":1793284775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726008043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"alternative-id":["S2666636726008043"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Pharmacokinetic Estimation of Melphalan Exposure Predicts Disease Control and Toxicity After Autologous Hematopoietic Cell Transplantation for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}